Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.63 |
| ▸ | BCHE | P06276 | 8/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654960 | 1.00 | ACHE (0.63) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL22911500 | 0.85 | SMN1; SMN2 (0.61) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL16955234 | 0.85 | ACHE (0.49) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL13877363 | 0.85 | ACHE (0.49) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL11449830 | 0.85 | KMT2A (0.48) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL683930 | 0.84 | ALDH1A1 (0.50) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL4225731 | 0.84 | ACHE (0.48) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL12778520 | 0.84 | LMNA (0.61) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL31606945 | 0.83 | ACHE (0.60) | ACHEBCHEHTTSMN1; SMN2LMNA | |
| SCHEMBL19121433 | 0.83 | ACHE (0.60) | ACHEBCHEHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595642-A2 | COMPOSITIONS COMPRISING DERIVATIVES OF ESSENTIAL OIL COMPOUNDS AND USE IN PERSONAL CARE PRODUCTS | The Procter and Gamble Company (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012012385-A2 | COMPOSITIONS COMPRISING DERIVATIVES OF ESSENTIAL OIL COMPOUNDS AND USE IN PERSONAL CARE PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2012-01-26 | — | — | WO | claimed |
| US-20120014883-A1 | Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products | THE PROCTER & GAMBLE COMPANY | 2012-01-19 | — | — | US | claimed |
| US-20250302014-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2025-10-02 | — | — | US | disclosed |
| US-20250100959-A1 | METHOD FOR STORING REDUCED COENZYME Q10 | KANEKA CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4518647-A1 | WASP PEST MANAGEMENT SYSTEM | Toner, Daradh (IE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4454643-A1 | METHOD FOR STORING REDUCED COENZYME Q10 | Kaneka Corporation (JP) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023214095-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023120552-A1 | PACKAGE AND PRESERVING METHOD FOR REDUCED COENZYME Q10 | 株式会社カネカ | 2023-06-29 | — | — | WO | disclosed |
| WO-2023120555-A1 | METHOD FOR STORING REDUCED COENZYME Q10 | 株式会社カネカ | 2023-06-29 | — | — | WO | disclosed |
| CN-109810062-B | Phenylimidazole derivative, synthesis method thereof and application of phenylimidazole derivative in pesticide | 云南农业大学 | 2022-06-17 | — | — | CN | disclosed |
| WO-2012012385-A2 | COMPOSITIONS COMPRISING DERIVATIVES OF ESSENTIAL OIL COMPOUNDS AND USE IN PERSONAL CARE PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120014883-A1 | Compositions Comprising Derivatives Of Essential Oil Compounds And Use In Personal Care Products | THE PROCTER & GAMBLE COMPANY | 2012-01-19 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| WO-2008153701-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | ACHE 2578/4885BCHE 3774/4885HTT 4493/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | ACHE 2578/4885BCHE 3774/4885HTT 4493/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | ACHE 4669/4885BCHE 4735/4885HTT 1562/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | ACHE 3384/4885BCHE 3430/4885HTT 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.